CTOs on the Move

Genesys Spine

www.genesysspine.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.genesysspine.com
  • 1250, South Capital of Texas Highway
    Austin, TX USA 78746
  • Phone: 512.381.7070

Executives

Name Title Contact Details

Similar Companies

UI Magic

UI Magic Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mankind Pharma

Mankind Pharma is one of the Indian leading pharmaceutical companies, and changes the pharma industry by providing world class medications at affordable prices and maintaining quality standards by using state-of-the-art technology for production of hig...

Paratek Pharmaceuticals

Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. As a commercial-stage biopharmaceutical company, we develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe that we have the right people, the right knowledge and the right drug to make a difference in patients` lives. Our Mission To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that advance our technology and strengthen Paratek. Our Vision To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.

Yusef Manufacturing Labs

Yusef Manufacturing Labs is a Kaysville, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Erytech

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.